Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefalotin (also known as cephalothin or sefalothin) is a semisynthetic first-generation cephalosporin antibiotic. It acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. Cefalotin is structurally related to other first-generation cephalosporins such as cefazolin and is administered parenterally (intravenous or intramuscular routes). Its primary indications include the prevention of infections during surgery and the treatment of a broad spectrum of infections including those affecting blood, bone or joints, respiratory tract, skin, and urinary tract[6][8][10]. The drug contains a beta-lactam moiety that makes it susceptible to degradation by beta-lactamases produced by some bacteria[10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefalotin.